MARKET

NVCN

NVCN

Neovasc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.370
-0.030
-1.25%
Closed 19:59 07/10 EDT
OPEN
2.430
PREV CLOSE
2.400
HIGH
2.435
LOW
2.350
VOLUME
153.85K
TURNOVER
--
52 WEEK HIGH
8.65
52 WEEK LOW
1.240
MARKET CAP
26.39M
P/E (TTM)
-0.5953
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average NVCN stock price target is 8.33 with a high estimate of 15.00 and a low estimate of 5.00.

EPS

NVCN News

More
FDA Ad Com set for Neovasc Reducer device
Seeking Alpha - Article · 3d ago
Neovasc Announces Circulatory System Devices Panel Meeting Date for Neovasc Reducer(TM) Device
Newsfile · 3d ago
Neovasc Reports FDA Circulatory System Devices Panel Will Review Premarket Approval Application For Neovasc Reducer Device At Oct. 27, 2020 Meeting
 Neovasc, Inc. (NASDAQ:NVCN) (TSX:NVCN) ("Neovasc" or the "Company"), announced today that it has been informed by the U.S. Food and Drug Administration (FDA) that the Circulatory System
Benzinga · 4d ago
Neovasc reports Q2 preliminary revenue
Neovasc (NASDAQ:NVCN) +0.8% reports Q2 preliminary revenue of ~$295,000 down from $440,420K due to a reduction in reducer procedures that began in mid-Marc
seekingalpha · 6d ago
Neovasc Provides Update on Second Quarter Results
Newsfile · 6d ago
Neovasc reports Q2 preliminary revenue
Seeking Alpha - Article · 6d ago
Neovasc Sees Q2 Sales About $295K; Co. Says 'Revenues were negatively impacted by a reduction in Reducer procedures that began in mid-March and persisted through early June,' Co. To Report Full Results Aug. 6
Benzinga · 6d ago
Neovasc Reducer(TM) and Tiara(TM) Featured at Leading Industry Virtual Conferences
Newsfile · 06/29 17:00

Industry

Advanced Medical Equipment & Technology
-0.60%
Healthcare Equipment & Supplies
-0.31%

Hot Stocks

Symbol
Price
%Change

About NVCN

Neovasc Inc. (Neovasc) is a specialty medical device company. The Company develops, manufactures and markets products for the cardiovascular marketplace. The Company's segment is the development, manufacture and marketing of medical devices. Its products include the Tiara technology in development for the transcatheter treatment of mitral valve disease, the Neovasc Reducer for the treatment of refractory angina, and tissue products. The Tiara is in preclinical/early clinical stage development to provide a minimally invasive transcatheter device for patients experiencing mitral regurgitation (MR) as a result of mitral heart valve disease. The Reducer is an hourglass-shaped, balloon-expandable, stainless steel, bare metal device, which is implanted in the coronary sinus, creating a restriction in venous outflow from the myocardium (the muscular layer of the heart wall). Neovasc produces Peripatch, a biological tissue product that is manufactured from pericardium.
More

Webull offers kinds of Neovasc Inc stock information, including NASDAQ:NVCN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVCN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NVCN stock methods without spending real money on the virtual paper trading platform.